Genmab company profile

GMAB · Nasdaq Copenhagen · DKK

Compare Genmab
kr 3,502.00Change from previous close: −0.77%Absolute change: −kr 27.00

Close · November 17, 2026

Company profile

Genmab has 3,244 employees and is headquartered in Copenhagen, Denmark.

Founded in 1998 and based in Copenhagen, Denmark, Genmab works on antibody-based medicines for cancer and other diseases. Its marketed products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Tivdak for recurrent or metastatic cervical cancer, and DARZALEX and DARZALEX FASPRO for multiple myeloma, and it has collaboration agreements with companies including AbbVie, Pfizer and Johnson & Johnson. Other products address lung cancer, multiple myeloma, multiple sclerosis and thyroid eye disease, and the pipeline spans solid tumors, ovarian cancer, sickle cell disease and hemophilia A.

In the fiscal year ended December 2025, revenue reached USD 3.7 billion, up 19.2% from the previous year, and net income was USD 963 million. The company had 3,244 employees and its headquarters are in Copenhagen. Its shares are also listed on NASDAQ.

Company facts

Industry
Biotechnology
Country
Denmark
Headquarters
Carl Jacobsens Vej 30, 2500, Copenhagen
Employees
3,244
Chief executive
Jan G.J. de Winkel
Founded
1998
Fiscal year
January - December
Listing
GMAB · Nasdaq Copenhagen
Currency
DKK
ISIN
DK0010272202
Website
genmab.com

Genmab and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
GenmabGMABDenmark$31.53B3,24430.6%46.2
UCBUCBBelgium$61.2B9,00029.5%25.7
Financière de TubizeTUBBelgium$11.78B30.0%109.0
ALK-AbellóALK.BDenmark$8.09B2,77326.9%40.7
ABIVAXABVXFrance$7.61B98-6,270.4%—
Bachem HoldingBANBSwitzerland$6.92B2,72521.8%39.2

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Genmab with its competitors